28 October 2020>: Clinical Research
Need for Greater Attention to Joint Damage in Rhupus Patients: Results from an Ultrasound Study
Zhi-Xin Chen 123BCE* , Pei-Dan Yang 12CDE* , Min-Ying Liu 12BCE* , Ping-Fang Song 4EF , Qiang Xu 12AEFG*DOI: 10.12659/MSM.927104
Med Sci Monit 2020; 26:e927104
Table 2 Laboratory manifestations of rhupus patients and SLE with arthropathy patients.
Laboratory manifestations | Rhupus | SLE with arthropathy | P value |
---|---|---|---|
ANA, n (%) | 10/10 (100.00%) | 33/33 (100.00%) | 0.641 |
ds-DNA, n (%) | 10/10 (100.00%) | 32/33 (96.97%) | 0.578 |
Anti-ENA antibody, n (%) | 7/10 (70.00%) | 32/33 (96.97%) | 0.011* |
Anti-Sm, n (%) | 1/10 (10.00%) | 9/33 (27.30%) | 0.258 |
Anti-SSA, n (%) | 7/10 (70.00%) | 21/33 (63.63%) | 0.712 |
Anti-SSB, n (%) | 2/10 (20.00%) | 8/33 (24.24%) | 0.781 |
Anti-Ro52, n (%) | 2/10 (20.00%) | 14/33 (42.42%) | 0.199 |
Anti-nRNP, n (%) | 1/10 (10.00%) | 15/33 (45.50%) | 0.042* |
Anti-rRNP, n (%) | 0/10 (0.00%) | 7/33 (21.21%) | 0.111 |
Anti-AnuA, n (%) | 5/10 (50.00%) | 18/33 (54.55%) | 0.801 |
Anti-AHA, n (%) | 2/10 (20.00%) | 15/33 (45.50%) | 0.149 |
Anti-CenpB, n (%) | 0/10 (0.00%) | 1/33 (3.00%) | 0.578 |
Anti-Scl70, n (%) | 0/10 (0.00%) | 1/33 (3.00%) | 0.578 |
LAC, n (%) | 0/5 (0.00%) | 9/28 (32.14%) | 0.137 |
ACA, n (%) | 1/6 (16.67%) | 1/27 (3.70%) | 0.216 |
CRP, mean (SD), mg/L | 36.471±10.232 | 14.243±2.639 | 0.004* |
ESR, mean (SD),mm/h | 66±14.72 | 44.13±4.709 | 0.068 |
C3, g/L, mean±SD | 0.811±0.110 | 0.559±0.047 | 0.020* |
C4, g/L, mean±SD | 0.139±0.012 | 0.118±0.013 | 0.363 |
RF. n (%) | 8/10 (80.00%) | 16/33 (48.48%) | 0.079 |
Anti-CCP, n (%) | 7/10 (70.00%) | 3/28 (10.71%) | ** |
RF, IU/ml, mean±SD | 798.212±653.235 | 60.624±18.873 | 0.045* |
Anti-CCP, IU/ml, mean±SD | 42.633±14.520 | 2.121±0.970 | ** |
LAC – lupus anticoagulant; ACA – anti-cardiolipin antibody; CRP – C reactive protein; ESR – erythrocyte sedimentation rate; RF – rheumatoid factor; anti-CCP – anti-cyclic citrullinated peptide antibody. * P ** P |